


## 产品名称: MS049

产品别名: MS049

生物活性:																	
Description	MS049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. MS049 reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 is not toxic and do not affect the growth of HEK293 cells[1].																
IC <sub>50</sub> & Target	IC50: 34 nM (PRMT4), 43 nM (PRMT6)[1]																
In Vitro	MS049 (0.1-10 μM; 20 hours) reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC <sub>50</sub> =0.97±0.05 μM)[1]. MS049 (0.1-100 μM; 72 hours) inhibits endogenous PRMT4 methyltransferase activity in a concentration dependent manner resulting in reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC <sub>50</sub> =1.4±0.1 μM) in HEK293 cells[1].																
Western Blot Analysis[1]																	
Cell Line:	HEK293 cells																
Concentration:	0.1, 1, 10 μM																
Incubation Time:	20 hours																
Result:	Reduced the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC <sub>50</sub> =0.97±0.05 μM).																
Western Blot Analysis[1]																	
Cell Line:	HEK293 cells																
Concentration:	0.1, 1, 10, 100 μM																
Incubation Time:	72 hours																
Result:	Reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC <sub>50</sub> =1.4±0.1 μM) in HEK293 cells.																
In Vitro:	DMSO : ≥ 31 mg/mL (124.82 mM) * "≥" means soluble, but saturation unknown.																
Preparing Stock Solutions	<table border="1"><thead><tr><th>Solvent / Mass Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td>4.0264 mL</td><td>20.1321 mL</td><td>40.2641 mL</td></tr><tr><td>5 mM</td><td>0.8053 mL</td><td>4.0264 mL</td><td>8.0528 mL</td></tr><tr><td>10 mM</td><td>0.4026 mL</td><td>2.0132 mL</td><td>4.0264 mL</td></tr></tbody></table>	Solvent / Mass Concentration	1 mg	5 mg	10 mg	1 mM	4.0264 mL	20.1321 mL	40.2641 mL	5 mM	0.8053 mL	4.0264 mL	8.0528 mL	10 mM	0.4026 mL	2.0132 mL	4.0264 mL
Solvent / Mass Concentration	1 mg	5 mg	10 mg														
1 mM	4.0264 mL	20.1321 mL	40.2641 mL														
5 mM	0.8053 mL	4.0264 mL	8.0528 mL														
10 mM	0.4026 mL	2.0132 mL	4.0264 mL														
Solvent&Solubility	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶																

	<p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline  <b>Solubility:</b> ≥ 2.5 mg/mL (10.07 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (10.07 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline)  <b>Solubility:</b> ≥ 2.5 mg/mL (10.07 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (10.07 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO →90% corn oil  <b>Solubility:</b> ≥ 2.5 mg/mL (10.07 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (10.07 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
<b>References</b>	[1]. <a href="#">Shen Y et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J Med Chem. 2016 Sep 15.</a>



# 源叶生物